Seeking Alpha

Insys cannabidiol tagged an Orphan Drug

  • The FDA designates Insys Therapeutics' (INSY) pharmaceutical cannabidiol an Orphan Drug for the treatment of Lennox-Gastaut Syndrome, a severe form of childhood-onset epilepsy characterized by multiple seizure types, moderate-to-severe cognitive impairment and an abnormal EEG.
  • Orphan Drug designation affords the developer certain incentives including extended marketing exclusivity.
Comments (1)
  • User 16202282
    , contributor
    Comments (202) | Send Message
     
    GWPH & INSY for the win!
    25 Jun, 05:25 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector